Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study

Background: Type 2 diabetes (T2D) increases the risk of many types of cancer. Dysregulation of proteasome-related protein degradation leads to tumorigenesis, while Exendin-4, a glucagon-like peptide 1 receptor (GLP-1R) agonist, possesses anti-cancer effects. Methods: We explored the co-expression of...

Full description

Bibliographic Details
Main Authors: Dandan Mao, Huanyi Cao, Mai Shi, Chi Chiu Wang, Joseph Kwong, Joshua Jing Xi Li, Yong Hou, Xing Ming, Heung Man Lee, Xiao Yu Tian, Chun Kwok Wong, Elaine Chow, Alice Pik Shan Kong, Vivian Wai Yan Lui, Paul Kay Sheung Chan, Juliana Chung Ngor Chan
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:EBioMedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396421000359
id doaj-9e1f6495be95480cab0266bd8b891aab
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Dandan Mao
Huanyi Cao
Mai Shi
Chi Chiu Wang
Joseph Kwong
Joshua Jing Xi Li
Yong Hou
Xing Ming
Heung Man Lee
Xiao Yu Tian
Chun Kwok Wong
Elaine Chow
Alice Pik Shan Kong
Vivian Wai Yan Lui
Paul Kay Sheung Chan
Juliana Chung Ngor Chan
spellingShingle Dandan Mao
Huanyi Cao
Mai Shi
Chi Chiu Wang
Joseph Kwong
Joshua Jing Xi Li
Yong Hou
Xing Ming
Heung Man Lee
Xiao Yu Tian
Chun Kwok Wong
Elaine Chow
Alice Pik Shan Kong
Vivian Wai Yan Lui
Paul Kay Sheung Chan
Juliana Chung Ngor Chan
Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study
EBioMedicine
Type 2 diabetes
Cancer
Exendin-4
PSMA
GLP-1R
author_facet Dandan Mao
Huanyi Cao
Mai Shi
Chi Chiu Wang
Joseph Kwong
Joshua Jing Xi Li
Yong Hou
Xing Ming
Heung Man Lee
Xiao Yu Tian
Chun Kwok Wong
Elaine Chow
Alice Pik Shan Kong
Vivian Wai Yan Lui
Paul Kay Sheung Chan
Juliana Chung Ngor Chan
author_sort Dandan Mao
title Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study
title_short Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study
title_full Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study
title_fullStr Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study
title_full_unstemmed Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study
title_sort increased co-expression of psma2 and glp-1 receptor in cervical cancer models in type 2 diabetes attenuated by exendin-4: a translational case-control study
publisher Elsevier
series EBioMedicine
issn 2352-3964
publishDate 2021-03-01
description Background: Type 2 diabetes (T2D) increases the risk of many types of cancer. Dysregulation of proteasome-related protein degradation leads to tumorigenesis, while Exendin-4, a glucagon-like peptide 1 receptor (GLP-1R) agonist, possesses anti-cancer effects. Methods: We explored the co-expression of proteasome alpha 2 subunit (PSMA2) and GLP-1R in the Cancer Genome Atlas (TCGA) database and human cervical cancer specimens, supplemented by in vivo and in vitro studies using multiple cervical cancer cell lines. Findings: PSMA2 expression was increased in 12 cancer types in TCGA database and cervical cancer specimens from patients with T2D (T2D vs non-T2D: 3.22 (95% confidence interval CI: 1.38, 5.05) vs 1.00 (0.66, 1.34) fold change, P = 0.01). psma2-shRNA decreased cell proliferation in vitro, and tumour volume and Ki67 expression in vivo. Exendin-4 decreased psma2 expression, tumour volume and Ki67 expression in vivo. There was no change in GLP-1R expression in 12 cancer types in TCGA database. However, GLP-1R expression (T2D vs non-T2D: 5.49 (3.0, 8.1) vs 1.00 (0.5, 1.5) fold change, P < 0.001) was increased and positively correlated with PSMA2 expression in T2D-related (r = 0.68)  but not in non-T2D-related cervical cancer specimens. This correlation was corroborated by in vitro experiments where silencing glp-1r decreased psma2 expression. Exendin-4 attenuated phospho-p65 and -IκB expression in the NF-κB pathway. Interpretation: PSMA2 and GLP-1R expression in T2D-related cervical cancer specimens was increased and positively correlated, suggesting hyperglycaemia might promote cancer growth by increasing PSMA2 expression which could be attenuated by Exendin-4. Funding: This project was supported by Postdoctoral Fellowship Scheme, Direct Grant, Diabetes Research and Education Fund from the Chinese University of Hong Kong (CUHK)
topic Type 2 diabetes
Cancer
Exendin-4
PSMA
GLP-1R
url http://www.sciencedirect.com/science/article/pii/S2352396421000359
work_keys_str_mv AT dandanmao increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT huanyicao increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT maishi increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT chichiuwang increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT josephkwong increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT joshuajingxili increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT yonghou increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT xingming increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT heungmanlee increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT xiaoyutian increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT chunkwokwong increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT elainechow increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT alicepikshankong increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT vivianwaiyanlui increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT paulkaysheungchan increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
AT julianachungngorchan increasedcoexpressionofpsma2andglp1receptorincervicalcancermodelsintype2diabetesattenuatedbyexendin4atranslationalcasecontrolstudy
_version_ 1724229425964253184
spelling doaj-9e1f6495be95480cab0266bd8b891aab2021-03-07T04:29:37ZengElsevierEBioMedicine2352-39642021-03-0165103242Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control studyDandan Mao0Huanyi Cao1Mai Shi2Chi Chiu Wang3Joseph Kwong4Joshua Jing Xi Li5Yong Hou6Xing Ming7Heung Man Lee8Xiao Yu Tian9Chun Kwok Wong10Elaine Chow11Alice Pik Shan Kong12Vivian Wai Yan Lui13Paul Kay Sheung Chan14Juliana Chung Ngor Chan15Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, ChinaDepartment of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, ChinaSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, ChinaDepartment of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China; Corresponding author at: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32 Ngan Shing St, Shatin, N.T., Hong Kong SAR, China.Background: Type 2 diabetes (T2D) increases the risk of many types of cancer. Dysregulation of proteasome-related protein degradation leads to tumorigenesis, while Exendin-4, a glucagon-like peptide 1 receptor (GLP-1R) agonist, possesses anti-cancer effects. Methods: We explored the co-expression of proteasome alpha 2 subunit (PSMA2) and GLP-1R in the Cancer Genome Atlas (TCGA) database and human cervical cancer specimens, supplemented by in vivo and in vitro studies using multiple cervical cancer cell lines. Findings: PSMA2 expression was increased in 12 cancer types in TCGA database and cervical cancer specimens from patients with T2D (T2D vs non-T2D: 3.22 (95% confidence interval CI: 1.38, 5.05) vs 1.00 (0.66, 1.34) fold change, P = 0.01). psma2-shRNA decreased cell proliferation in vitro, and tumour volume and Ki67 expression in vivo. Exendin-4 decreased psma2 expression, tumour volume and Ki67 expression in vivo. There was no change in GLP-1R expression in 12 cancer types in TCGA database. However, GLP-1R expression (T2D vs non-T2D: 5.49 (3.0, 8.1) vs 1.00 (0.5, 1.5) fold change, P < 0.001) was increased and positively correlated with PSMA2 expression in T2D-related (r = 0.68)  but not in non-T2D-related cervical cancer specimens. This correlation was corroborated by in vitro experiments where silencing glp-1r decreased psma2 expression. Exendin-4 attenuated phospho-p65 and -IκB expression in the NF-κB pathway. Interpretation: PSMA2 and GLP-1R expression in T2D-related cervical cancer specimens was increased and positively correlated, suggesting hyperglycaemia might promote cancer growth by increasing PSMA2 expression which could be attenuated by Exendin-4. Funding: This project was supported by Postdoctoral Fellowship Scheme, Direct Grant, Diabetes Research and Education Fund from the Chinese University of Hong Kong (CUHK)http://www.sciencedirect.com/science/article/pii/S2352396421000359Type 2 diabetesCancerExendin-4PSMAGLP-1R